Targeting the TGF-β-p21 axis: a critical regulator of bleomycin-induced cell cycle arrest and apoptosis in vitro-implication for progressive cervical cancer therapy.

Somi Shrivastava, Chandrahas Koumar Ratnacaram

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Somi ShrivastavaCancer Research and Therapeutics Division, Yenepoya Research Centre, Yenepoya (Deemed to Be) University, Mangalore, 575018, Karnataka, India.

Chandrahas Koumar RatnacaramCancer Research and Therapeutics Division, Yenepoya Research Centre, Yenepoya (Deemed to Be) University, Mangalore, 575018, Karnataka, India. rckoumar@yenepoya.edu.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer signifies a global health concern and is a major cause of cancer mortality in women worldwide. Dysregulation of apoptotic pathway and cell cycle play a role in cancer development. Aberrant signalling pathways leads to complex mechanisms leading to the severity. Bleomycin is an anti-tumor glycopeptide molecule which exhibits impressive cytotoxicity in cancer cells. However, its modulating significance on TGF-β induced cell cycle arrest and apoptosis in cervical cancer remains elusive. We confirmed the cytotoxicity, anti proliferative effect of bleomycin in HeLa cells. Meanwhile, bleomycin also led to the suppression of cell migration, invasion. Relative gene expression quantification for cell cycle regulatory, apoptotic, and TGF-β member's genes was done by qRT-PCR. Bleomycin markedly downregulated the expression of cyclin A2, cyclin B1 and cell cycle arrest at G

Indexed as

Antibiotics, AntineoplasticApoptosisBleomycinCell Cycle CheckpointsCyclin-Dependent Kinase Inhibitor p21Transforming Growth Factor betaUterine Cervical NeoplasmsCell MovementCell ProliferationFemaleHeLa CellsHumansSignal TransductionAntibiotics, AntineoplasticBleomycinCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Transforming Growth Factor betaBleomycinCell cycle arrestCell cycle inhibitorsCervical cancerGADD45ATumor suppressor

Identifiers

PMID40019671

DOI10.1007/s12032-025-02624-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.